KIR3DL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In fact, KIR AA haplotypes, which include many KIR inhibitors such as KIR3DL1, are associated with better outcomes in TKI-treated CML patients [77] and are also linked to patients with sustained TFR [8,75].